Jialong(SZ:002495)2025-01-23 08:40Financial Performance - The estimated net profit for 2024 is projected to be between 19 million and 28 million yuan, compared to a loss of 44.71 million yuan in the same period last year[3]. - The estimated net profit after deducting non-recurring gains and losses is expected to be between 18.2 million and 27.2 million yuan, compared to a loss of 15.06 million yuan in the previous year[3]. - The basic earnings per share is projected to be between 0.0205 yuan and 0.0302 yuan, compared to a loss of 0.0478 yuan per share last year[3]. - Non-recurring gains and losses are expected to impact net profit by approximately 800,000 yuan, mainly from financial product income and government subsidies[7]. - The financial data in this earnings forecast has not been audited by an accounting firm, and investors are advised to exercise caution[8]. Cost Management and Efficiency - The decrease in prices of major raw materials, such as monosodium glutamate and disodium guanylate, has led to a reduction in sales costs and an increase in gross profit margin[5]. - The company has strengthened internal cost management and efficiency improvement measures, resulting in a substantial increase in operating performance compared to the previous year[6]. Marketing Strategies - The company has implemented marketing strategies and market reforms that have shown significant results, contributing to the positive performance of its main business[5].